Premium
First‐in‐Class Angiotensin Receptor Neprilysin Inhibitor in Heart Failure
Author(s) -
Vardeny O,
Tacheny T,
Solomon S D
Publication year - 2013
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2013.146
Subject(s) - neprilysin , sacubitril , valsartan , heart failure , natriuretic peptide , ejection fraction , pharmacology , angiotensin ii , angiotensin receptor , medicine , npr2 , clinical pharmacology , chemistry , receptor , blood pressure , biochemistry , enzyme
Neprilysin inhibitors augment the natriuretic peptide system by preventing the breakdown of atrial natriuretic peptide and B‐type natriuretic peptide. LCZ696, an angiotensin receptor neprilysin inhibitor composed of a neprilysin inhibitor prodrug and the angiotensin receptor antagonist valsartan, has proven effective in hypertension, has shown promise in a pilot trial of heart failure with preserved ejection fraction, and is being tested in a large outcomes trial of heart failure with reduced ejection fraction. A preserved ejection fraction outcomes trial is beginning. Clinical Pharmacology & Therapeutics (2013); 94 4, 445–448. doi: 10.1038/clpt.2013.146